Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder
PAIN-iRBD
2 other identifiers
interventional
24
1 country
1
Brief Summary
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, with over 12 million patients expected globally by 2040. The disease is currently diagnosed at the appearance of motor symptoms, but by then, over 60% of striatal dopaminergic neurons have already been destroyed. Prodromal symptoms such as idiopathic REM Sleep Behavior Disorder (iRBD), anosmia, mood disorders and constipation appear earlier and are listed as criteria for a prodromal PD diagnosis. Identifying early signs is critical to initiate neuroprotective treatments as early as possible. While pain is prevalent and highly disabling in early PD, no data are currently available on pain perception in iRBD patients, whose condition is of the main risk factor for PD development.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 16, 2026
CompletedFirst Posted
Study publicly available on registry
January 26, 2026
CompletedStudy Start
First participant enrolled
February 24, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2026
May 1, 2026
April 1, 2026
5 months
January 16, 2026
April 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Comparison of the intensity of chronic pain between patients with iRBD and a control group of patients
Measuring the Visual Analog Scale (VAS) between patients with iRBD without diagnosis of PD and a control group of patients diagnosed with narcolepsy type 1 who present RBD (Rapid eye movement sleep behavior disorder).
2 hours after the inclusion
Secondary Outcomes (5)
Describe semiological characteristics of pain in RBD patients
2 hours after the inclusion
Compare the presence of chronic pain
2 hours after the inclusion
Assessing Pain Characteristics
2 hours after the inclusion
Assessment of thermal pain threshold and tolerance
2 hours after the inclusion
Assessment of correlations between the intensity of chronic pain
2 hours after the inclusion
Study Arms (2)
Idiopathic REM sleep Behavior disorder (iRBD) Group
EXPERIMENTALPatients who have an idiopathic REM sleep Behavior Disorder
Idiopathic REM Sleep Bhavior Disorder (iRBD) + narcolepsy type 1
ACTIVE COMPARATORpatients who have an iRBD and who have type 1 narcolepsy
Interventions
Patients will undergo a pain test, also called a thermotest, which consists of determining pain thresholds using a thermometer applied to the hand.
Patients will complete various questionnaires about pain
Patients will complete questionnaires
Eligibility Criteria
You may qualify if:
- Diagnosed with iRBD confirmed by polysomnography;
- No clinical diagnosis of Parkinson's disease or other diagnosis of neurodegenerative disease;
- Ability to understand and complete study procedures and questionnaires;
- Control group:
- Diagnosed with narcolepsy type 1;
- Coexisting REM sleep behavior disorder confirmed by polysomnography;
- Ability to understand and complete study procedures and questionnaires;
You may not qualify if:
- Diagnosed Parkinson's Disease, dementia with Lewy bodies or multiple system atrophy;
- Severe depression according to Diagnostic and Statistical Manual of Mental Disorders (DSM V);
- Inability to complete study procedures or questionnaires.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre Expert Parkinson Hôpital Pierre Paul Riquet Place du Docteur Baylac
Toulouse, 31059, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 16, 2026
First Posted
January 26, 2026
Study Start
February 24, 2026
Primary Completion (Estimated)
August 1, 2026
Study Completion (Estimated)
August 1, 2026
Last Updated
May 1, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share